What Bend Bioscience does

Bend Bioscience is a U.S. pharmaceutical contract development and manufacturing organization (CDMO) formed in April 2025 from the unification of CoreRx, Societal CDMO, and Bend Bioscience under a single brand. The company serves innovator pharmaceutical and biotechnology companies developing small molecule drug products, providing integrated Design, Develop, and Manufacture services from pre-clinical through commercial scale. Its core capabilities center on enabling technologies for small molecule oral dosage forms, including spray dried dispersions for bioavailability enhancement, particle engineering for powders for inhalation, modified release formulations (sustained, extended, delayed, pulsatile), multiparticulates (Wurster coating, extrusion-spheronization, MUPS), oral solids, oral liquids with pediatric and geriatric formulation expertise, and topical formulations. Supporting service lines include preformulation and process design, analytical and stability testing, technology transfer, and packaging with serialization.

The company operates three FDA-, EMA-, ANVISA-, and DEA-inspected U.S. facilities totaling over 300,000 ft²: Bend, Oregon (R&D and clinical manufacturing with particle engineering and spray drying center-of-excellence); Gainesville, Georgia (commercial manufacturing center-of-excellence for modified release and multiparticulates, with 45+ years of operating heritage); and Clearwater, Florida (preformulation, oral liquids, and low-volume commercial manufacturing). Commercial capacity includes hundreds of millions of dosage units per year at the Georgia site, with a GEA PSD-4 commercial-scale spray dryer (1,250 kg/h gas flow) coming online in 2026.

Bend Bioscience generates revenue through fee-for-service CDMO contracts spanning preformulation, formulation development, analytical testing, cGMP clinical manufacturing, and long-term commercial supply agreements. The go-to-market is enterprise direct sales targeting biotech and pharma decision-makers, supplemented by active participation in industry events such as CPHI, DCAT Week, Drug Delivery and Formulation Summit, and PODD. Pricing is project-specific and quote-based; no public pricing is disclosed. Recent commercial partnerships include an exclusive U.S. manufacturing agreement with Cingulate Inc. for ADHD treatment CTx-1301 through 2028 and a development agreement with Starton Therapeutics for an oral controlled release dosage form of STAR-LLD (lenalidomide).

Name

Bend Bioscience

Legal name

CoreRx, Inc., and Societal CDMO, Inc.

Website

https://bendbioscience.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Bend Bioscience is a U.S. pharmaceutical CDMO formed in 2025 from the unification of CoreRx, Societal CDMO, and Bend Bioscience, serving innovator pharma and biotech with integrated design, development, and manufacturing of small molecule oral dosage forms across three U.S. facilities.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ)

Keywords

• Pharmaceutical CDMO services
• Contract development manufacturing
• Oral dosage formulation
• Bioavailability enhancement
• Small molecule manufacturing

Headquarters

HQ city

Bend

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Fee-for-service CDMO model providing pharmaceutical development and manufacturing services to biotech and pharma companies. Services span preformulation, formulation development, analytical testing, clinical manufacturing, and commercial manufacturing. Revenue generated through project-based contracts, typically multi-year agreements for product development and supply.
2. Commercial Manufacturing Supply: Long-term commercial supply agreements for approved drug products, providing ongoing manufacturing capacity and reliable supply to pharmaceutical clients.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Bend Bioscience is a pharmaceutical finished-product CDMO providing integrated contract development and manufacturing services for small molecule drug products across three U.S. facilities. The company offers design, development, and cGMP manufacturing services spanning preformulation, formulation, analytical testing, Phase 1-3 clinical manufacturing, commercial manufacturing, packaging, and technology transfer for oral solids, oral liquids, topicals, and powders for inhalation.

Product overview

Bend Bioscience is a U.S.-based pharmaceutical CDMO formed from the unification of CoreRx, Societal CDMO, and Bend Bioscience, offering integrated Design, Develop, and Manufacture services for small molecule drug products from pre-clinical through commercial scale. The company's service portfolio centers on enabling technologies including Oral Bioavailability Enhancement (spray dried dispersions, hot melt extrusion, lipid-based formulations), Modified Release (sustained, extended, delayed, pulsatile delivery), Multiparticulates (drug-loaded pellets with custom release profiles), and Oral Dosage Form Design. Supporting these core capabilities are specialized service offerings: Oral Solids, Oral Liquids, Topicals, and Powders for Inhalation for diverse dosage forms; Develop Services providing CMC development from preformulation through scale-up; cGMP Clinical Manufacturing and Commercial Manufacturing for Phase 1-3 through market supply; Analytical & Stability Services for comprehensive testing; Technology Transfer for production transitions; Packaging Services for integrated primary packaging; and Quality & Compliance ensuring FDA, EMA, ANVISA, and DEA regulatory adherence. The company operates three specialized U.S. facilities in Bend, Oregon (particle engineering, spray drying, early-phase development), Gainesville, Georgia (commercial oral solids, modified release, multiparticulates), and Clearwater, Florida (preformulation, oral liquids, low-volume commercial) providing end-to-end development and manufacturing solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Design Services Strategic formulation design integrating fundamental science with innovative problem solving. Evaluates API properties and architects solutions for formulation and process to ensure product performance and manufacturability for pharmaceutical and biotech clients.
• Develop Services Applied science and engineering transforming product design into robust manufacturable products through full CMC development, spanning preformulation, analytical development, feasibility, prototyping, and scale-up for pharmaceutical clients.
• cGMP Clinical Manufacturing Phase 1-3 clinical supply manufacturing across a wide range of oral solid and liquid dosage forms with phase-appropriate controls, regulatory readiness, and supply continuity planning for pharma and biotech sponsors.
• Commercial Manufacturing Reliable commercial manufacturing for oral solids and liquids with on-time-in-full (OTIF) performance including tablets, capsules, oral liquids, and GMP packaging with serialization for approved drug products.
• Analytical and Stability Services Fully-equipped on-premise analytical development, QC, and stability testing including spectroscopy, chromatography, dissolution, and ICH stability condition testing for pharmaceutical development and commercial programs.
• Technology Transfer Cross-disciplinary, transparent technology transfer services to move finished product production including project management, quality and regulatory strategy, gap analysis, and risk assessment for pharmaceutical clients.
• Packaging Services On-site oral solid and oral liquid dose packaging integrated with manufacturing, including clinical packaging, commercial bottling, blistering, serialization, and aggregation for pharmaceutical clients.
• Quality and Compliance Comprehensive quality systems and regulatory compliance with proven track record of FDA, EMA, ANVISA, and DEA inspections and cGMP manufacturing standards for pharmaceutical and biotech clients.
• Oral Bioavailability Enhancement Enhances oral absorption for poorly bioavailable molecules using amorphous solid dispersion technology including spray dried dispersions, hot melt extrusion, and lipid-based formulations to enable brick dust and lipophilic APIs for pharmaceutical clients.
• Modified Release Controlled release formulation services enabling sustained, extended, delayed, pulsatile, or targeted drug delivery profiles to reduce peak-to-trough fluctuations and improve patient convenience, with 35+ years of experience in oral-controlled-release products.
• Multiparticulates Drug-loaded and polymer-coated pellets providing custom release profiles, consistent pharmacokinetics, and flexible dosing options through capsules, sachets, or MUPS tablets for pharmaceutical clients.
• Topicals Topical product design and development from benchtop to 500L scale with thermo/thermoreversible gel processing for localized treatment to reduce systemic side effects, serving pharmaceutical clients.
• Powders for Inhalation Expert particle engineering for spray-dried powders for inhalation using dry powder inhaler (DPI) formulations with optimized aerodynamic performance and consistent particle attributes for pharmaceutical clients.

Quantifiable outcome

• Superior on-time, in-full (OTIF) delivery rate for clinical and commercial programs
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Cingulate Inc.coreStrategic or Co-development Partner · 17 September 2025Exclusive manufacturing partnership for CTx-1301, a next-generation ADHD treatment. Bend serves as the sole U.S. manufacturer through 2028, contingent on FDA approval. Partnership supports Cingulate's preparation for potential market entry with manufacturing security.
• Starton TherapeuticscoreStrategic or Co-development Partner · 24 June 2025Development agreement for oral controlled release dosage form of STAR-LLD (lenalidomide). Bend provides drug delivery R&D support, manufacturing capabilities, and scale-up for Starton's lead candidate - a proprietary oral sustained release formulation designed to improve tolerability and efficacy of lenalidomide for multiple myeloma and chronic lymphocytic leukemia treatment.
• Lanier Technical CollegeminorOthersWorkforce development partnership including an apprenticeship program designed to prepare students for careers in pharmaceutical sciences with hands-on training and foundational skills.

Scale indicators8 records

Recent moves11 records

Expansion highlights8 records

Broad incumbents

• Recipharm: Global CDMO offering oral solid dose, sterile, and semi-solid manufacturing services. Comparable in serving biotech and pharma clients with commercial supply needs; broader geographic reach than Bend but similarly focused on small molecule drug product manufacturing.
• PCI Pharma Services: Integrated pharmaceutical services provider offering drug development, manufacturing, packaging, and commercialization services. Comparable in offering integrated CDMO plus packaging services with focus on serving small-to-mid biotech and pharma clients across clinical and commercial stages.
• Catalent: One of the largest global pharmaceutical CDMOs offering oral, injectable, and biologic drug product development and commercial manufacturing. Broad incumbent with overlapping oral solid dose and bioavailability capabilities but at much greater scale than Bend, serving the same biotech and pharma client base.
• Thermo Fisher Scientific (Patheon): Operates one of the largest global pharmaceutical CDMO businesses (formerly Patheon) covering oral solids, sterile, APIs, and biologics. Broad incumbent serving the same pharma/biotech customer base as Bend but with substantially larger scale, broader dosage form capabilities, and global footprint.
• Lonza Pharma & Biotech: Global CDMO leader with small molecule API and drug product capabilities including oral solids and bioavailability enhancement technologies. Comparable to Bend in offering integrated development-to-commercial services but with global footprint and significantly larger scale. Dan Dobry, Bend's CSO, previously led Lonza commercial development.

Emerging players

• Aprecia Pharmaceuticals: Pharmaceutical CDMO using proprietary 3D-printing (ZipDose) technology for oral dosage forms. Bend's CEO Owen Murray was most recently CEO of Aprecia, indicating strategic alignment. Comparable in serving biotech clients with novel oral delivery needs, though differentiated by 3DP technology versus Bend's spray drying/modified release focus.

Direct peers

• Ascendia Pharmaceuticals: Specialty CDMO focused on complex oral formulations including poorly soluble molecules using nanoemulsions, amorphous dispersions, and lipid-based systems. Direct peer to Bend's bioavailability enhancement and modified release capabilities serving biotech clients with challenging molecules.
• Halo Pharma: U.S.-based CDMO offering oral solid and liquid dose development and commercial manufacturing for small molecules. Direct peer to Bend with overlapping capabilities in clinical and commercial oral solid dose manufacturing, serving similar biotech and specialty pharma customers.
• Quotient Sciences: CDMO specializing in oral drug product development and clinical manufacturing with integrated formulation and clinical testing capabilities. Direct competitor in small molecule oral solid dose formulation, bioavailability enhancement, and clinical-to-commercial transitions.
• Adare Pharmaceuticals: Specialty CDMO focused on oral drug delivery technologies including modified release, multiparticulates, and taste-masking. Direct peer to Bend's modified release and multiparticulate capabilities, serving similar biotech and specialty pharma customers with similar enabling technology platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bend-bioscience
• Xx.com/Bend_Bioscience

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bend Bioscience